Fate Therapeutics Inc (FATE) — SEC Filings
Fate Therapeutics Inc (FATE) — 35 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 13 8-K, 8 SC 13G/A, 6 10-Q.
View Fate Therapeutics Inc on SEC EDGAR
Overview
Fate Therapeutics Inc (FATE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: FATE THERAPEUTICS INC reported a net loss of $32.25 million for the three months ended September 30, 2025, a 32.4% improvement from the $47.68 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $103.94 million, down from $134.11 million in 202
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Fate Therapeutics Inc is neutral.
Filing Type Overview
Fate Therapeutics Inc (FATE) has filed 6 10-Q, 13 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of FATE's 27 recent filings, 2 were flagged as high-risk, 18 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5.28M |
| Net Income | -$103.94M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $40.62M |
| Operating Margin | N/A |
| Total Assets | $343.67M |
| Total Debt | N/A |
Key Executives
- Dr. Wayne Johnson
- Dr. Nicole A. Shinton
- Dr. Wayne V. Saville
- Dr. Nicole T. Williams
- Dr. Adam L. Rosenthal
- Dr. Nicole A. Shuman
- Dr. Jeffrey S. W. Smith
- Dr. Paul R. Hastings
- Dr. Jeffrey W. Runge
- Dr. Wayne P. Yetman
- Jennifer Ciresi
- Aaron I. Davis
- Joe Lewis
Industry Context
The cell therapy market is characterized by rapid innovation and significant investment, but also faces challenges related to manufacturing complexity, high development costs, and evolving regulatory pathways. Companies like Fate Therapeutics are at the forefront of developing novel approaches, but compete with a growing number of players, including large pharmaceutical companies with substantial resources.
Top Tags
corporate-governance (5) · biotech (5) · amendment (4) · filing (4) · institutional-ownership (4) · Biotechnology (3) · 10-Q (3) · biotechnology (3) · executive-change (2) · personnel (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $103.94M | Decreased 22.5% from $134.11M in 2024, indicating improved financial efficiency. |
| Collaboration Revenue (9 months) | $5.28M | Decreased significantly from $11.77M in 2024, highlighting reduced partnership income. |
| Research and Development Expenses (9 months) | $82.40M | Reduced from $101.39M in 2024, reflecting cost-cutting measures. |
| General and Administrative Expenses (9 months) | $35.86M | Decreased from $58.91M in 2024, showing operational streamlining. |
| Cash and Cash Equivalents | $40.62M | Increased from $36.06M at December 31, 2024, despite ongoing losses. |
| Restructuring Charges | $1.1M | Incurred for severance in Q3 2025 due to workforce reduction. |
| Common Stock Shares Outstanding | 115,352,289 | As of November 6, 2025, indicating potential dilution from prior periods. |
| Net Loss | $62.3 million | for the three months ended June 30, 2025, an increase from $50.1 million in the prior-year period. |
| Revenue | $10.5 million | for the three months ended June 30, 2025, a 17.9% decrease from $12.8 million in the prior-year period. |
| Research and Development Expenses | $55.8 million | for the three months ended June 30, 2025, up from $48.2 million in the prior-year period. |
| Accumulated Net Losses | $2.1 billion | since inception through June 30, 2025. |
| Fiscal Year End | 12-31 | Indicates the end of the company's financial reporting year. |
| Net Income | N/A | Specific net income figures not detailed in this excerpt. |
| Cash Flow | N/A | Specific cash flow figures not detailed in this excerpt. |
| Fiscal Year | FY24 | Executive compensation details pertain to this period. |
Forward-Looking Statements
- {"claim":"Boxer Capital, LLC will maintain or increase its stake in Fate Therapeutics, Inc. over the next 6-12 months.","entity":"Boxer Capital, LLC","targetDate":"2025-02-12","confidence":"medium"}
- {"claim":"Fate Therapeutics, Inc. will see increased institutional investor interest following this disclosure.","entity":"Fate Therapeutics, Inc.","targetDate":"2024-08-12","confidence":"medium"}
- {"claim":"Fate Therapeutics' stock price may experience downward pressure due to the institutional exit.","entity":"Fate Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might review their positions in Fate Therapeutics following this divestment.","entity":"Institutional Investors","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Fate Therapeutics Inc (FATE)?
Fate Therapeutics Inc has 35 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FATE filings?
Across 35 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Fate Therapeutics Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Fate Therapeutics Inc (FATE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Fate Therapeutics Inc?
Key financial highlights from Fate Therapeutics Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FATE?
The investment thesis for FATE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Fate Therapeutics Inc?
Key executives identified across Fate Therapeutics Inc's filings include Dr. Wayne Johnson, Dr. Nicole A. Shinton, Dr. Wayne V. Saville, Dr. Nicole T. Williams, Dr. Adam L. Rosenthal and 8 others.
What are the main risk factors for Fate Therapeutics Inc stock?
Of FATE's 27 assessed filings, 2 were flagged high-risk, 18 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Fate Therapeutics Inc?
Recent forward-looking statements from Fate Therapeutics Inc include guidance on {"claim":"Boxer Capital, LLC will maintain or increase its stake in Fate Therapeutics, Inc. over the next 6-12 months.", and 3 other predictions.